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Abstract: Tedizolid and linezolid have antibacterial activity against the most important acute bacterial
skin and skin-structure infection (ABSSSIs) pathogens. The objective of this work was to apply PK/PD
analysis to evaluate the probability of attaining the pharmacodynamic target of these antimicrobials
based on the susceptibility patterns of different clinical isolates causing ABSSSI. Pharmacokinetic and
microbiological data were obtained from the literature. PK/PD breakpoints, the probability of target
attainment (PTA) and the cumulative fraction of response (CFR) were calculated by Monte Carlo
simulation. PTA and CFR are indicative of treatment success. PK/PD breakpoints of tedizolid and
linezolid were 0.5 and 1 mg/L, respectively. Probability of treatment success of tedizolid was very
high (>90%) for most staphylococci strains, including MRSA and coagulase-negative staphylococci
(CoNS). Only for methicillin- and linezolid-resistant S. aureus (MLRSA) and linezolid resistant (LR)
CoNS strains was the CFR of tedizolid very low. Except for LR, daptomycin-non-susceptible (DNS),
and vancomycin-resistant (VRE) E. faecium isolates, tedizolid also provided a high probability of
treatment success for enterococci. The probability of treatment success of both antimicrobials for
streptococci was always higher than 90%. In conclusion, for empiric treatment, PK/PD analysis has
shown that tedizolid would be adequate for most staphylococci, enterococci, and streptococci, even
those LR whose linezolid resistance is mediated by the cfr gene.
Keywords: tedizolid; linezolid; PK/PD; acute bacterial skin and skin-structure infections
1. Introduction
Linezolid, the first commercialized oxazolidinone antibiotic, has activity against a wide
variety of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus [1].
Regardless of the patient’s hepatic or renal function, the authorized dose of linezolid
is 600 mg every 12 h. Tedizolid phosphate is the second commercially available oxazo-
lidinone antibiotic, with antibacterial activity against the most important acute bacterial
skin and skin-structure infection (ABSSSIs) pathogens, including some linezolid-resistant
Staphylococcus aureus and enterococci [2]. Tedizolid, like linezolid, inhibits bacterial protein
synthesis by binding to 23S rRNA of the 50S subunit of the ribosome. It has been approved
in several countries, including the United States, the European Union, and Canada [3].
Although it is similar to linezolid, tedizolid has a modified side chain at the C-5
position of the oxazolidinone nucleus that confers activity against some linezolid-resistant
strains and possesses an optimized C- and D-ring system that increases potency through
additional binding site interactions. Tedizolid offers theoretical advantages: on the one
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hand, it is dosed once daily [4]; on the other hand, it is a more potent protein synthesis
inhibitor, enabling it to overcome chloramphenicol-florfenicol resistance mechanisms
(cfr gene) [5]. Like linezolid, the dose of tedizolid does not need to be modified in patients
with renal impairment, hepatic impairment, on hemodialysis, or whenever switching from
intravenous to oral administration [6].
Tedizolid is four- to eightfold more potent in vivo than linezolid against all species
of staphylococci, enterococci, and streptococci, including drug-resistant phenotypes such
as methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE)
and linezolid-resistant (LR) phenotypes whose linezolid resistance is mediated by the
cfr gene [7]. The cfr gene, due to its ubiquity, plays an important role in the spread of
drug resistance. In terms of drug resistance mechanism, the cfr gene confers resistance
through a non-mutated mechanism, while linezolid resistance is mainly due to gene
mutations. Specifically, the cfr gene belongs to the methylated transferases, which can
act on the binding site of linezolid and methylate at position 2503 of the 23S rRNA gene,
thus making bacteria resistant to linezolid. The cfr gene has been identified in clinical
linezolid-resistant Gram-positive bacteria, indicating that the presence of the cfr gene is an
important mechanism of bacterial resistance to linezolid [8,9].
In multicenter, randomized, double-blind, and non-inferiority trials, the efficacy and
safety of tedizolid and linezolid were compared for the treatment of Gram-positive ABSSSI
infections (intravenous tedizolid 200 mg once daily for 6 days, or intravenous linezolid
600 mg twice daily for 10 days) [10,11]. In these studies (Establish-1 and Establish-2),
clinical response was high (>70%) and similar with both antibiotics.
Although tedizolid and linezolid have a similar safety profile, tedizolid seems to
present a lower incidence of gastrointestinal adverse effects and bone marrow suppression
than linezolid [12]. Tolerability in clinically important subpopulations (obese, elderly,
renal impairment, hepatic disease/impairment) appears to be comparable to the overall
population [13].
In order to preserve both new and older antimicrobials, it is critical to evaluate if the
dose administered to the patient is sufficient to provide the necessary exposure for optimal
clinical response. The success of the therapy depends on the characteristics of the patient,
the pharmacokinetic profile of the antibiotic, and the susceptibility of the microorganism
responsible for the infection [14]. In fact, inadequate dose selection is one of the most
common reasons why drug development programs fail to achieve New Drug Application
(NDA) approval [15].
To maximize the likelihood of a favorable clinical/microbiological response, and to
minimize the probability of exposure-related toxicity, pharmacokinetic/pharmacodynamic
(PK/PD) modelling represents a very useful tool for dose regimen decision-making. The
use of Monte Carlo simulation provides an estimate of the antibiotic dosing regimen’s
probability of achieving the targeted pharmacodynamic exposure, given uncertainty in
patient pharmacokinetics and the minimum inhibitory concentration (MIC) distribution
of the bacterial population [16]. The study of PK/PD is an iterative process whereby pre-
clinical (in vitro and in vivo) experiments, population PK models, and in silico simulations
are used to investigate potential dosing regimens and PK/PD targets. These studies can be
used to inform regimen selection for clinical studies [17]. In the field of antibacterial agents,
the guidelines of the European Medicine Agency (EMA, Amsterdam, The Netherlands)
and its Committee for Medicinal Products for Human Use (CHMP, London, UK) on the
evaluation of medicinal products include PK/PD studies [18].
PK/PD analysis integrates information about the concentration of the drug that
reaches the infection site and induces the therapeutic response, and the susceptibility of
the pathogen against the antibiotic, expressed as the MIC. The quantitative relationship
between a pharmacokinetic parameter and a microbiological parameter is known as a
PK/PD index. For tedizolid and linezolid, the PK/PD index that best correlates with
efficacy is the ratio of the area under the free drug concentration–time curve at steady state
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over 24 h to the MIC (f AUC24/MIC). The magnitude required for antimicrobial efficacy
has been established as 3 for tedizolid and 80 for linezolid [19–21].
In this work, we evaluated by PK/PD analysis and Monte Carlo simulation the activity
of tedizolid and compared it to linezolid, with the objective of predicting the probability of
treatment success considering the susceptibility profile of staphylococci, enterococci, and
streptococci reported in Europe and the United States.
2. Results
Figure 1 shows the fAUC24/MIC for tedizolid (200 mg q24h) and linezolid (600 mg q12).
The PK/PD breakpoint, which is the highest MIC value at which there is a high probability
of target attainment, can be read directly from the figure at the intersection of the horizontal
line at the PK/PD target and the lower limit of the 95% confidence interval (2.5% percentile).
For tedizolid (PK/PD target: f AUC24/MIC ≥ 3), the PK/PD breakpoint was 0.5 mg/L,
and for linezolid (PK/PD target: f AUC24/MIC ≥ 80) it was 1 mg/L.
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Figure 1. Relationship between f AUC24/MIC and MIC for tedizolid (200 mg q24h) and linezolid
(600 mg q12h).
Table 1 features the PTA values of both antimicrobials for an MIC range from 0.12 to
16 mg/L. PTA is defined as the probability that the specific value of the PK/PD index asso-
ciated with the efficacy is achieved at a certain MIC value. In other words, it corresponds
to the percentage of simulated patients with the estimated PK/PD index equal to or higher
than the value related to efficacy against a pathogen with a certain MIC [14]. Simulation
results confirm that for the selected targets, standard doses of tedizolid and linezolid cover
infections with MIC values up to 0.5 and 1 mg/L, respectively.
Table 1. Probability of target attainment (PTA) for tedizolid (200 mg q24h) and linezolid (600 mg q12h).
Probability of Target Attainment, PTA (%)
MIC (mg/L)
PK/PD Target 0.06 0.125 0. 0.5 1 2 8 16
Tedizolid f AUC24/MIC ≥ 3 100 100 100 97 55 11 1 0 0
Linezolid f AUC24/MIC ≥ 80 100 100 100 100 97 62 19 4 0
In grey PTA values ≥ 90% (high probability of success).
Tables 2–4 show the susceptibility pattern of tedizolid and linezolid for staphylococci,
e te ococci, nd streptococci comp led from different studies who reported MIC data of
these microorganisms for the two antibiotics. The tables include resistance phenotype,
number of isolates, collection eriod, and a timicrobial activity. The rates of isolates
inhibited at every MIC value were used for Monte Carlo simulations.
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Table 2. Resistance phenotype, number of isolates, collection period, and antimicrobial activity of staphylococci for tedizolid and linezolid.
Microorganism/Study Antimicrobial Resistance Phenotype Nº Isolates Collection Period Percent of Isolates (%) Inhibited at MIC (mg/L) of:
≤0.12 0.25 0.5 1 2 4 8 >8
S. aureus




Linezolid 0.2 0.3 27.2 67.8 4.2 0.0 0.3
Zurenko et al. [23]
Tedizolid
7187 2008–2013
7.7 62.3 29.8 0.2 0.1 0.1
Linezolid 0.1 0.3 21.6 72.8 4.9 0.0 0.2
Rodríguez-Avial et al. [24] Tedizolid LR 5 2010–2011
100
Linezolid 60.0 40.0
Pfaller [25] Tedizolid 4364 2014–2015 95.2 4.8
MRSA
Sahm et al. [22]
Tedizolid
1770 2011–2012
12.7 53.2 33.8 0.1 0.1 0.1
Linezolid 0.2 0.3 30.8 65.7 2.7 0.0 0.3




20.8 45.9 31.6 1.7
VISA 100 59.0 25.0 16.0
DNS 75 30.7 50.6 18.7
LR 7 28.6 28.5 0 42.9












Pfaller et al. [25] Tedizolid 1006 2014–2015 96.6 3.4
CoNS
Sahm et al. [22] Tedizolid 537 2011–2012 51.4 39.1 8.6 0 0 0.7
Zurenko et al. [23] Tedizolid 674 2008–2013
47.9 40.6 10.0 0.7 0.0 0.6 0.2
Linezolid 0.9 23.2 61.2 12.6 1.2 0.1 0.8
Rodríguez-Avial et al. [24] Tedizolid LR 164 2010–2011
1.2 2.5 12.2 6.1 7.3 49.4 20.1 1.2
Linezolid LR 4.3 95.7
Pfaller et al. [25] Tedizolid 729 2014–2015 98.6 1.2 0 0 0.1
Light grey: values under the susceptibility range. DNS: daptomycin-non-susceptible; LR: linezolid resistant; hVISA: heterogeneous vancomycin intermediate; VISA: vancomycin intermediate; MRSA:
methicillin-resistant S. aureus, MLRSA: methicillin- and linezolid-resistant S. aureus.
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Table 3. Resistance phenotype, number of isolates, collection period, and antimicrobial activity of enterococci for tedizolid and linezolid.
Microorganism/Study Antimicrobial Resistance Phenotype Nº Isolates Collection Period
Percent of Isolates (%) Inhibited at MIC (mg/L) of:
≤0.12 0.25 0.5 1 2 4 8 >8
E. faecalis
Sahm et al. [22] Tedizolid 634 2011–2012 5.8 54.8 39.1 0.1 0.2
Barber et al. [26] Tedizolid 100 Before 2016 30.0 69.0 1.0
Pfaller et al. [25] Tedizolid 559 2014–2015 55.6 44.0 0.4
E. faecium
Sahm et al. [22] Tedizolid 221 2011–2012 10.4 52.5 35.7 0.9 0.5
Barber et al. [26] Tedizolid
120
Before 2016
5.0 42.5 26.7 20.8 2.5 2.5
LR 10 40.0 30.0 30.0
DNS 25 44.0 12.0 32.0 8.0 4.0
Pfaller et al. [25] Tedizolid
311
2014–2015
80.4 18.6 0.6 0.0 0.3
VRE 245 79.2 20.0 0.8
VSE 66 84.8 13.6 0.0 1.5
MIC (mg/L)
Klupp et al. [28]
2 4 8 16 32 64 128 256
Tedizolid VRE
30 2012–2015
20.0 60.0 10.0 3.3 6.7
Linezolid VRE 26.7 20.0 20.0 33.3
Enterococcus spp. (predominantly E. faecalis and E. faecium without differentiating species) MIC (mg/L)≤0.12 0.25 0.5 1 2 4 8 >8
Zurenko et al. [23] Tedizolid 1241 2008–2013
5.7 50.7 42.2 1.0 0.3 0.1
Linezolid 0.4 2.7 40.7 54.4 1.4 0.1 0.3
Other enterococci






10.4 52.2 36.2 0.6 0.6




Linezolid VSE 0.1 0.5 5.9 51.9 41.3 0.3
Light grey: values under the susceptibility range. DNS: daptomycin-non-susceptible; LR: linezolid resistant; VRE: vancomycin resistant; VSE: vancomycin susceptible.
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Table 4. Resistance phenotype, number of isolates, collection period, and antimicrobial activity of streptococci for tedizolid and linezolid.
Microorganism/Study Antimicrobial Resistance Phenotype Nº Isolates Collection Period Percent of Isolates (%) Inhibited at MIC (mg/L) of:
S. pneumoniae 0.094 0.125 0.19 0.25 0.38
Hipp et al. [29] Tedizolid Penicillin-susceptible 56 2009–2016 1.8 3.6 57.1 35.7 1.8
MIC (mg/L)
0.064 0.125 0.25 0.5 1 2 4
EUCAST [30] Linezolid 60,180 0.1 1.0 7.8 65.3 25.9
MIC (mg/L)
Pfaller et al. [25] 0.015 0.03 0.06 0.12 0.25 0.5 1
Tedizolid 1273 2014–2015 0.3 0.5 6.4 72.5 20.2
Streptococcus spp. MIC (mg/L)
Zurenko et al. a [23] 0.06 0.12 0.25 0.5 1 2 4
Tedizolid
1600 2008–2013
5.00 44.38 50.13 0.50
Linezolid 3.50 26.13 65.13 5.19 0.06
S. anginosus group
Zurenko et al. b [23] Tedizolid
91 2008–2013
38.46 43.96 17.58
Linezolid 38.46 35.16 26.37
S. viridans group
Pfaller et al. c [25] Tedizolid 218 2014–2015 38.53 59.17 2.29
β-hemolytic streptococci
Pfaller et al. d [25] Tedizolid 2014–2015 93.5 4.5
a Includes S. pyogenes, S. agalactiae, S. groups C, F, and G, and S. viridans group; b Includes isolates of S. anginosus, S. intermedius, and S. constellatus; c Includes S. anginosus, S. anginosus group, S. australis,
S. constellatus, S. cristatus, S. gordonii, S. infantis, S. lutetiensis, S. massiliensis, S. mitis, S. mitis group, S. mitis/oralis, S. mutans, S. oralis, S. parasanguinis, S. salivarius, S. salivarius group, and S. sanguinis. d Includes
S. agalactiae, S. canis, S. dysgalactiae, and S. pyogenes. Light grey: values under the susceptibility range.
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Monte Carlo simulation allowed us to estimate the cumulative fraction of response
(CFR), defined as the expected population PTA for a specific drug dose and a specific
population of microorganisms. This index must be understood as the expected probability
of success of a dosing regimen against bacteria in the absence of the specific value of
MIC, and thus the population distribution of MICs is used. Table 5 shows the probability
of success (expressed as CFR) of tedizolid and linezolid for staphylococci considering
the susceptibility rates reported in the different studies. CFR values close to 100% were
obtained with tedizolid for S. aureus, and for all strains of MRSA except linezolid-resistant
(LR) isolates reported by Barber et al. [26] and methicillin- and linezolid-resistant S. aureus
(MLRSA) isolates reported by Peñuelas et al. [27]. CFR with tedizolid was close to 100%
for LR CoNS isolates reported by Rodríguez-Avial et al. [24]. Linezolid only provided CFR
values higher than 90% for CoNS strains from the study of Zurenko et al. [23].
Table 5. Probability of success (expressed as CFR or cumulative fraction of response) of tedizolid and
linezolid for staphylococci.
Microorganism/Study Resistance Phenotype Probability of Success (CFR, %)
Tedizolid Linezolid
S. aureus
Sahm et al. [22] 99 69
Zurenko et al. [23] 99 67
Rodríguez-Avial et al. [24] LR 97 3
Pfaller et al. [25] 100 n.c.
MRSA
Sahm et al. [22] 71




Peñuelas et al. [27] MRSA 99 75
MLRSA 62 n.c.
Pfaller et al. [25] 100 n.c.
CoNS
Sahm et al. [22] 94 n.c.
Zurenko [23] 99 93
Rodríguez-Avial et al. [24] LR 20 0
Pfaller et al. [25] 100 n.c.
DNS: daptomycin-non-susceptible; LR: linezolid resistant; hVISA: heterogenous vancomycin intermediate; VISA:
vancomycin intermediate; MRSA: methicillin-resistant S. aureus, MLRSA: methicillin- and linezolid-resistant
S. aureus. n.c.: not calculated due to lack of MIC data.
Table 6 features the CFR values of tedizolid and linezolid for enterococci. For E. faecalis
and other enterococci, tedizolid provided CFR ranging from 98% to 100%. Regarding
E. faecium, CFR was higher than 85% except for the daptomycin-non-susceptible (DNS)
and vancomycin-resistant (VR) isolates from the study of Barber et al. [26] and VR isolates
from the study of Pfaller et al. [25]. CFR values obtained for linezolid was 80% when using
the MIC distribution provided by Zurenko et al. [23], who reported the susceptibility rates
of enterococci without differentiating species, although E. faecium and E. faecalis were the
most represented. When considering the MIC distribution reported by Klupp et al. [28],
CFR was 0 for both linezolid and tedizolid. For other enterococci, the CFR obtained for
linezolid ranged from 79% to 85%.
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Table 6. Probability of success (expressed as CFR) of tedizolid and linezolid for enterococci.
Microorganism/Study Resistance Phenotype Probability of Success (CFR, %)
Tedizolid Linezolid
E. faecalis
Sahm et al. [22] 99 n.c.
Barber et al. [26] 100 n.c.
Pfaller et al. [25] 100 n.c.
E. faecium
Sahm et al. [22] 99 n.c.
Barber et al. [26] 86 n.c.
LR 25 n.c.
DNS 75 n.c.
Klupp et al. [28] VRE 0 0
Pfaller et al. [25] 100 n.c.
VRE 100 n.c.
VSE 99 n.c.
Enterococcus spp. (predominantly E. faecalis and E. faecium)
Zurenko et al. [23] 98 80
Other enterococci
Sahm et al. [22] 99 n.c.
VRE 98 79
VSE 100 85
DNS: daptomycin-non-susceptible; LR: linezolid resistant; VRE: vancomycin resistant; VSE: vancomycin suscepti-
ble. n.c.: not calculated due to lack of MIC data.
The CFR values of both antimicrobials for streptococci are presented in Table 7. Ir-
respective of the microorganism, the CFR of tedizolid was always 100%, and the CFR of
linezolid varied from 91% to 98%.
Table 7. Probability of success (expressed as CFR or cumulative fraction of response) of tedizolid and
linezolid for streptococci.
Microorganism/Study Resistance Phenotype Probability of Success (CFR, %)
Tedizolid Linezolid
S. pneumoniae
Hipp et al. [29] Penicillin-susceptible 100 n.c.
EUCAST et al. [30] 91
Pfaller [25] 100 n.c.
Streptococcus spp.
Zurenko et al. [23] 100 98
S. anginosus group
Zurenko et al. [23] 100 98
S. viridans group
Pfaller et al. [25] 100 n.c.
β-hemolytic
streptococci
Pfaller et al. [25] 100 n.c.
n.c.: not calculated due to lack of MIC data.
3. Discussion
Linezolid, the first representative member of the oxazolidinone family introduced into
the pharmaceutical market, shows excellent activity; however, in recent years, resistance
to microorganisms (mainly MRSA) has emerged [31]. Due to the limited number of thera-
peutic options available for ABSSSIs, new therapeutic alternatives have been developed,
especially for resistant Gram-positive microorganisms. In fact, the development of new
generations of antimicrobials is one of the most accepted strategies to mitigate the current
and future impact of antimicrobial resistance. One of the new antibiotics developed to treat
Antibiotics 2021, 10, 755 9 of 14
ABSSSIs is tedizolid, which has greater potency, a better spectrum of activity, and a lower
resistance profile [2].
PK/PD analysis and Monte Carlo simulation have proved to be very useful tools
to select adequate antibiotic treatments with the goal of increasing efficacy and reducing
the risk of selecting multidrug-resistant isolates [32]. The use of PK/PD analyses can
ameliorate this risk and improve the likelihood of selecting an effective dose regimen,
thereby increasing the likelihood of success. These tools have also been applied to identify
changes in the antimicrobial activity of antibiotics, providing complementary information
to the simple assessment of MIC values [33–35], and to establish PK/PD breakpoints [14]
as well.
In this work, we calculated the PK/PD breakpoint of tedizolid and linezolid based
on the likelihood of obtaining a targeted exposure. PK/PD breakpoints can be estimated
as the highest MIC value at which a high probability of target attainment is obtained
(PTA ≥ 90%). Another option to estimate the breakpoints is by graphical representation of
the PK/PD index as a function of the MIC [36], which provides a much more restrictive
PK/PD breakpoint. In our study, the PK/PD breakpoint for tedizolid was 0.5 mg/L, and
it was 1 mg/L for linezolid. For S. aureus, the tedizolid PK/PD breakpoint matched the
epidemiologic cutoff value ECOFF—that is, the highest MIC for organisms devoid of phe-
notypically detectable acquired resistance mechanisms [21]. At present, there is no clinical
nor ECOFF breakpoint defined for enterococci, so the PK/PD breakpoint may be especially
useful when considering this antibiotic as a treatment option. An important advantage of
PK/PD breakpoints, as opposed to the clinical ones, is that they are species-independent.
In addition, they consider the antibiotic exposure—that is, they are calculated for a specific
dosage regimen, and therefore they help to optimize the selection of doses. Regarding strep-
tococci, tedizolid clinical breakpoints have only been defined for β-hemolytic groups A, B,
C, and G streptococci and the S. anginosus group. For these species, the PK/PD breakpoint
agrees with the current clinical breakpoint defined at 0.5 mg/L. Regarding linezolid, the
PK/PD breakpoint we calculated (1 mg/L) is lower than the clinical breakpoints (4 mg/L
for staphylococci and enterococci, and 2 mg/L for streptococci). However, according to the
linezolid-EUCAST rationale document for clinical breakpoints [20], Monte Carlo simula-
tions and target attainment rates for 600 mg twice a day support a susceptible breakpoint
of less than 1 or 2 mg/L, which is in agreement with our PK/PD breakpoint. According to
Mouton [37], the use of pharmacokinetic parameters from different populations in Monte
Carlo simulations for established dosing regimens results in different breakpoints. When
discrepancies in breakpoints are observed, the PK/PD breakpoints are generally lower than
those defined by the CLSI or EUCAST [32], as seen in the present study. Consequently, and
compared to tedizolid, the qualification of an isolate as susceptible for linezolid according
to the MIC value and the clinical breakpoint may be less useful in guiding therapy.
The highest MIC values that provided a PTA value ≥90% (0.5 mg/L for tedizolid
and 1 mg/L for linezolid, see Table 1) agree with the PK/PD breakpoints considering the
EUCAST approach [36]. According to our results, a high probability of treatment success
is expected with tedizolid if infection is due to microorganisms with MIC ≤ 0.5 mg/L.
Looking through the MIC values reported in Europe and the USA, irrespective of the
microorganism (Tables 2–4), most isolates would be covered by the standard dose of
tedizolid. In the case of linezolid, a high probability of treatment success would be achieved
for MIC ≤ 1 mg/L.
CFR is an index that estimates the probability of target attainment for an MIC distri-
bution, and it is very useful to predict the probability of treatment success when applied
empirically. For staphylococci (Table 5), tedizolid was adequate for most isolates, including
LR, heterogenous vancomycin intermediate (hVISA), vancomycin intermediate (VISA),
CoNS, and MRSA. Delpech et al. [38] demonstrated that tedizolid remains active against
staphylococci strains harboring the cfr gene, probably due the sterically compact nature
of the hydroxymethyl group of this drug. The potential spread of cfr-mediated linezolid
resistance in S. aureus makes tedizolid very useful for treating infections due to multidrug-
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resistant Gram-positive pathogens. Only for MLRSA reported by Peñuelas et al. [27]
(18 isolates) and LR CoNS isolates reported by Rodríguez-Avial et al. [24] (164 isolates), the
probability of treatment success is low (62% and 20%, respectively). The genetic basis for
linezolid resistance in isolates reported by Rodríguez-Avial et al. [24] was not studied, but
the susceptibility rates and CFR value indicate that resistance to tedizolid was not related
to the cfr gene.
Regarding enterococci (Table 6), tedizolid was adequate for E. faecalis, regardless of the
MIC provided by the different studies (CFR or probability of treatment success of 99–100%).
The same is applicable to other enterococci. For E. faecium, tedizolid also provides a
high probability of treatment success, except for the LR and DNS isolates reported by
Barber et al. [26] and the VRE isolates reported by Klupp et al. [28], in which the cfr gene
was not present. In fact, resistance associated with the cfr gene is not predominant in
enterococci; alterations in 23S rRNA remain the main oxazolidinone-resistance mechanism
in E. faecium, while the optrA gene prevails in E. faecalis [39,40]. Tedizolid represents a
therapeutic option only for a limited subset of LR-VRE strains [28]. Regarding linezolid,
only Sahm et al. [22] and Zurenko et al. [23] provide susceptibility rates for enterococci,
and according to them, linezolid provides a moderate probability of treatment success
when used for infections due to enterococci (even VRE and VSE).
Finally, both tedizolid and linezolid are expected to provide a high probability of
treatment success when used for infections due to streptococci (Table 7). These results were
expected due to the high susceptibility profile of streptococci to oxazolidinones.
Our results are based on simulations, and a number of considerations are assumed.
A previous work [41] reports the main limitations of PK/PD analysis and Monte Carlo
simulation. First, pharmacokinetic parameters in the specific population must be used
since it is known that pathophysiological conditions affect the distribution and elimination
of antimicrobials. In our study, the CL of tedizolid was obtained from pooled data from
seven densely and sparsely sampled clinical trials, most subjects were healthy, and the CL
of linezolid used was from healthy subjects. Second, pharmacokinetic equations used to
estimate drug exposure are usually simple models that facilitate calculations. Third, the
simulations in our work were based on serum pharmacokinetics, and therefore the results
are mainly applicable to bloodstream infections. Moreover, PK/PD modelling is based on
prior studies that have identified correlations between PK/PD indices and health outcomes.
These relationships have typically been derived from animal models; however, a good
correlation and validation between animal models and the clinic has been established.
4. Materials and Methods
This study was performed in different steps: (1) acquisition of pharmacokinetic
parameters, PK/PD targets, and susceptibility data; and (2) PK/PD analysis and Monte
Carlo simulation.
4.1. Pharmacokinetic Parameters, PK/PD Targets, and Susceptibility Data
The PK parameters of linezolid and tedizolid, as well as the PK/PD targets, were
obtained from published studies [19–21,42,43]. These data are presented in Table 8.
Table 8. Pharmacokinetic parameters and PK/PD targets of tedizolid and linezolid used for Monte Carlo simulations. CL
data are expressed as mean ± standard deviation.
Antibiotic DosingRegimen CL (L/h) Fu PK/PD Target References
Tedizolid 200 mg q24h 6.69 ± 2.07 0.10 f AUC24/MIC ≥ 3 [19,21,42]
Linezolid 600 mg q12h 4.80 ± 1.74 0.69 f AUC24/MIC ≥ 80 [19,20,43]
CL: total body clearance; Fu: unbound fraction; fAUC24: area under the unbound concentration–time curve over a period of 24 h.
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The CL value of tedizolid was obtained with a population PK model developed with
data from four phase 1 studies, one phase 2 study, and three phase 3 studies, in which
tedizolid was administered by either intravenous or oral route. The CL of linezolid is for
healthy volunteers.
The antimicrobial activity of linezolid and tedizolid for staphylococci, enterococci, and
streptococci were obtained from the literature [22–30]. We selected those studies that pro-
vided MIC values for both antibiotics. Clinical isolates from Europe and the United States
were collected between 2011 and 2016. Tables 2–4 show the MIC values of staphylococci,
enterococci, and streptococci, respectively, obtained from the abovementioned studies. The
MIC distribution of the isolates from the different studies was used for the PK/PD analysis.
4.2. Pharmacokinetic/Pharmacodynamic Analysis and Monte Carlo Simulation
Monte Carlo simulation is an advanced statistical modeling tool that makes it possible
to expand the sample size considering the variability of the PK and PD parameters on the
estimation of the PK/PD indices in order to provide predictions of the likely result of different
therapeutic approaches, or the achievement of therapeutic targets [14]. A 10,000-subject Monte
Carlo simulation was conducted for each antibiotic using Oracle® Crystal Ball Fusion Edition
v.11.1.2.3.500 (Oracle USA Inc., Redwood City, CA). The values of fAUC24/MIC (the ratio
of the area under the free drug concentration–time curve at steady state over 24 h to MIC)
were calculated for tedizolid (200 mg q24h) and linezolid (600 mg q12h) over an MIC range of
serial two-fold dilutions from 0.06 to 16 mg/L and from 0.06 to 128 mg/L, respectively. The
following equation was used [32]:
f AUC24/MIC = D × Fu/CL (1)
where D is the daily dose, Fu is the unbound fraction, and CL is the total clearance.
For simulations, a log-normal distribution was assumed for CL, according to statistical
criteria. Unbound fraction was included as a fixed value [44].
For every MIC value and considering the variability of the CL, the output of the
simulation consisted of a probability distribution, and the mean value and the 95% CI
(expressed as percentiles) of the f AUC24/MIC were extracted. The PK/PD breakpoint,
considered as the highest MIC value at which f AUC24/MIC is ≥3 or ≥80 for tedizolid and
linezolid, respectively, were estimated. According to EUCAST, the PK/PD breakpoint was
obtained from the lower limit of the 95% CI (2.5% percentile) [36].
The PTA [45], defined as the probability that a specific value of a PK/PD index
associated with the efficacy of the antimicrobial treatment is achieved at a certain MIC, was
estimated. PTA ≥80% but <90% was associated with moderate probabilities of success,
whereas PTA ≥ 90% was considered as optimal against that bacterial population [32].
CFR values, which allowed us to calculate the probability of success of an empiric
treatment, were calculated considering the PTA for each MIC value and the bacterial






where i indicates the MIC category, PTAi is the PTA of each MIC category, and Fi is the
fraction of the microorganism population in each MIC category. As with PTA, CFR ≥80%
but <90% was associated with moderate probabilities of success, whereas CFR ≥ 90% was
considered as optimal against that bacterial population [32].
5. Conclusions
In conclusion, PK/PD breakpoints calculated for tedizolid and linezolid were 0.5 and
1 mg/L, respectively. For empiric treatment, tedizolid seems to be adequate for the treat-
ment of infections due to most staphylococci, enterococci, and streptococci. For LR isolates
not related to the cfr gene, tedizolid does not guarantee efficacy. This study confirms the
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importance of considering the susceptibility profile of the geographical area or hospital
setting and the PK/PD analysis to guide empiric therapy.
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